ALACEPRIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H26N2O5S
Molecular Weight	406.496
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(O)=O

InChI

InChIKey=FHHHOYXPRDYHEZ-COXVUDFISA-N

InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H26N2O5S
Molecular Weight	406.496
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6323222
Curator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C66443

Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 94 Target ID: CHEMBL4074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3009814	Inhibitor 8504		17.0 nM [IC50]
Angiotensin-converting enzyme 94 Target ID: CHEMBL1808 Sources: DOI: 10.1111/j.1527-3466.1992.tb00238.x \| https://animal.ds-pharma.co.jp/html/english/pdf/alacepriltablet_201305.pdf	Inhibitor 8504		2.9 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 575 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018343s087lbl.pdf	Primary	Approved 8583	CAPOTEN Approved Use Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). Launch Date 1981
Heart Failure 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018343s087lbl.pdf	Primary	Approved 8583	CAPOTEN Approved Use Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). Launch Date 1981
Left Ventricular Dysfunction 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018343s087lbl.pdf	Primary	Approved 8583	CAPOTEN Approved Use Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). Launch Date 1981
Diabetic Nephropathy 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018343s087lbl.pdf	Primary	Approved 8583	CAPOTEN Approved Use Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). Launch Date 1981
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6280740	Primary	Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
878 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
824 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.31 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6324834/	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
800 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
230 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL DISULFIDE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
385 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
499 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1235 μg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1197 μg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
20.1 μg × h/L/(mg dose) REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	2.5 mg single, intravenous dose: 2.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
21 μg × h/L/(mg dose) REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
20.5 μg × h/L/(mg dose) REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1150 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
260 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL DISULFIDE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
870 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1067 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.2 h REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.1 h REVIEW https://pubmed.ncbi.nlm.nih.gov/3292102/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CAPTOPRIL blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6324834/	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3899460	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		CAPTOPRIL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED
0.83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	CAPTOPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
33% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26142561/			CAPTOPRIL serum	Homo sapiens

Doses

Dose	Population	Adverse events
50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1457272	unhealthy, 54 years (range: 39-65 years) Health Status: unhealthy Age Group: 54 years (range: 39-65 years) Sources: https://pubmed.ncbi.nlm.nih.gov/1457272	Sources: https://pubmed.ncbi.nlm.nih.gov/1457272
50 mg 1 times / day multiple, oral Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10225674	unhealthy, 65 years Health Status: unhealthy Age Group: 65 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/10225674	Disc. AE: Eruption lichenoid... AEs leading to discontinuation/dose reduction: Eruption lichenoid (severe, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10225674
750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1758810	healthy, 22 Health Status: healthy Age Group: 22 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/1758810	Disc. AE: Hypotension, Loss of consciousness... AEs leading to discontinuation/dose reduction: Hypotension Loss of consciousness Sources: https://pubmed.ncbi.nlm.nih.gov/1758810
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3286910	healthy, 33 Health Status: healthy Age Group: 33 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3286910	Disc. AE: Hypotension, Drowsiness... AEs leading to discontinuation/dose reduction: Hypotension Drowsiness Sources: https://pubmed.ncbi.nlm.nih.gov/3286910
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9074572	unhealthy, 73 Health Status: unhealthy Age Group: 73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9074572	Disc. AE: Cough, Failure heart... AEs leading to discontinuation/dose reduction: Cough (3.8%) Failure heart (2.4%) Hyperkalaemia (1.6%) Taste perversion Decreased appetite Rash (1%) Hypotension (1.4%) Angio-oedema (0.8%) Arrhythmia (1%) Myocardial infarction (1%) Kidney dysfunction (0.8%) Stroke (0.8%) Angina (0.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/9074572
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6753911	unhealthy Health Status: unhealthy Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6753911	Disc. AE: Urticaria, Hypotension... AEs leading to discontinuation/dose reduction: Urticaria (1.2%) Hypotension (2.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/6753911
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018343s084lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018343s084lbl.pdf	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018343s084lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 P-gp 1741 OAT1 725 MATE1 415 OCT2 779	OAT3 391 OAT1 395

Drug as perpetrator

Target	Modality	Activity
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20053795/	no
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20567254/	no
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23620485/	no
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19953504/	yes
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20053795/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 395	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28179375/\|https://pubmed.ncbi.nlm.nih.gov/23686349/	yes
OAT3 391	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28179375/\|https://pubmed.ncbi.nlm.nih.gov/19953504/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3380	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3380
ChemicalBook	CB6206769	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6206769
eMolecules	489049	https://www.emolecules.com/cgi-bin/more?vid=489049
MolPort	MolPort-001-794-639	https://www.molport.com/shop/molecule-link/MolPort-001-794-639
Selleck Chemicals	captopril-capoten	http://www.selleckchem.com/products/captopril-capoten.html
ZINC	ZINC000000057001	http://zinc15.docking.org/substances/ZINC000000057001

PubMed

Title	Date	PubMed
Effects of high-dose alacepril on left atrial pressure and central aortic pressure in awake dogs with mitral valve regurgitation.	2019-03	30819428
Effects of the angiotensin-converting enzyme inhibitor alacepril in dogs with mitral valve disease.	2018-08-10	29937457
Pharmacodynamics of alacepril in healthy cats.	2017-06	26927816
Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.	2016-09	27364087
[Successful extubation in a patient with alacepril-induced tongue angioedema].	2010-04	20420150
Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure.	2008-01	18360015
The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha.	2004	15720832
Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril.	2003-08	12948030
Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure.	2002-12	12390293
Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study.	2002-02	11862975
Spatial and temporal analysis of left ventricular filling flow propagation in hypertensive patients before and after regression of myocardial hypertrophy with alacepril therapy.	2001-08	11567592
Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives.	1985-01	2981324

Patents

Sample Use Guides

In Vivo Use Guide

Single oral dose (5 - 80 mg)

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:24:56 GMT 2025` Edited by `admin` on `Mon Mar 31 18:24:56 GMT 2025`
Record UNII	X39TL7JDPF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALACEPRIL

Official Name

English

CETAPRIL

Preferred Name

English

ALACEPRIL [MI]

Common Name

English

DU-1219

Code

English

N-(1-((S)-3-MERCAPTO-2-METHYLPROPIONYL)-L-PROLYL)-3-PHENYL-L-ALANINE ACETATE (ESTER)

Common Name

English

alacepril [INN]

Common Name

English

1-((2S)-3-(ACETYLTHIO)-2-METHYL-1-OXOPROPYL)-L-PROLYL-L-PHENYLALANINE

Systematic Name

English

ALACEPRIL [MART.]

Common Name

English

1-(D-3-ACETYLTHIO-2-METHYLPROPANOYL)-L-PROLYL-L-PHENYLALANINE

Common Name

English

ALACEPRIL [JAN]

Common Name

English

Alacepril [WHO-DD]

Common Name

English

NSC-338157

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C247